New Advances in Diabetes Drugs Transforming Treatment of Liver Disease
GLP-1 RAs, particularly semaglutide, are showing robust clinical data for liver disease with significant rates of disease resolution and improvement in liver fibrosis.
Research News
36 stories across all digests
New Research Suggests Thymus Gland Plays Greater Role Than Previously Understood
The thymus — source of thymosin peptides including Thymosin Alpha-1 — has become an emerging target for healthspan, longevity, and precision oncology research.
GLP-1 Medications Show Promise for Treating Addiction in 600,000+ Veteran Study
A BMJ-published study of over 600,000 US veterans found GLP-1 medications tied to reduced risk of substance use disorders across all major addictive substances, plus reduced overdose and death risk.
GLP-1 Medications Increase Testosterone Levels in Men With Obesity
New research shows semaglutide, dulaglutide, and tirzepatide can increase testosterone levels in men with obesity, adding another ancillary benefit to the GLP-1 portfolio.
Cyclic Peptide Delivery System Makes Oral Insulin Viable
Kumamoto University's DNP cyclic peptide system achieved roughly one-third to nearly half the effectiveness of injected insulin in animal studies — a major advance for oral insulin delivery.
GLP-1 Drugs May Pose Disproportionate Risks for EDS Patients
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.
Optimizing Copper Peptide GHK-Cu Through Next-Generation Delivery
Dermatology Times Q&A explores advances in GHK-Cu delivery for skincare, discussing how the peptide complexes with copper in human plasma and new formulation approaches to improve topical efficacy.
Washington Post: Comprehensive Guide to GLP-1 Drug Effects on the Body
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
Stanford Breakthrough: Reverse Translation Enables Peptide-to-DNA Sequencing
Stanford researchers developed a method converting peptide sequences into DNA for standard sequencing, published in Nature Biotechnology. Could dramatically accelerate peptide drug discovery.
New Cyclic Peptide Could Replace Insulin Injections With Daily Pills
Kumamoto University researchers developed cyclic peptide D-DNP-V that escorts insulin through the gut, achieving one-third to nearly half the effectiveness of injected insulin in mice.
Quarter of Weight Loss Persists After Stopping GLP-1 Drugs
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.
Experts Propose 10-Year Trial to Test GLP-1 Drugs for Cancer Prevention
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
Combination CGRP Monoclonal Antibodies and Gepants Safe for Migraine Prevention
Retrospective study found combining CGRP monoclonal antibodies with gepants is a safe and well-tolerated dual-mechanism migraine prevention approach.
CGRP Treatment Reduces Migraine Frequency in Multiple Sclerosis Patients
Retrospective cohort study showed significant migraine frequency reduction with favorable safety for patients with comorbid MS taking CGRP-targeted treatments.
GLP-1 Adherence Shows Significant Drop-Off After 1 Year
New data shows GLP-1 adherence drops significantly after the first year, with cost as a major factor. Insurance gaps and lack of mandated weight loss coverage pose barriers.
Cyclic Peptide Platform Enables Oral Insulin With 33-41% Bioavailability
Kumamoto University researchers developed a cyclic peptide (DNP peptide) that enables oral insulin delivery through the intestinal wall — a dramatic improvement that could end the century-long dependence on injections.
Semaglutide Linked to 42% Drop in Psychiatric Hospital Visits
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.
BPC-157 Evidence Review: 544 Papers, Only 3 Human Studies, Zero RCTs
In-depth review examined 544 BPC-157 papers and found only 3 human studies and zero randomized controlled trials. Author recommends most people avoid it until stronger evidence emerges.